These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 23704984)
1. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. Larsen MJ; Kruse TA; Tan Q; Lænkholm AV; Bak M; Lykkesfeldt AE; Sørensen KP; Hansen TV; Ejlertsen B; Gerdes AM; Thomassen M PLoS One; 2013; 8(5):e64268. PubMed ID: 23704984 [TBL] [Abstract][Full Text] [Related]
2. Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients. Walker LC; Thompson BA; Waddell N; ; Grimmond SM; Spurdle AB PLoS Genet; 2010 Feb; 6(2):e1000850. PubMed ID: 20174566 [TBL] [Abstract][Full Text] [Related]
3. RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families. Larsen MJ; Thomassen M; Tan Q; Lænkholm AV; Bak M; Sørensen KP; Andersen MK; Kruse TA; Gerdes AM BMC Med Genomics; 2014 Jan; 7():9. PubMed ID: 24479546 [TBL] [Abstract][Full Text] [Related]
4. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180 [TBL] [Abstract][Full Text] [Related]
5. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures. Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669 [TBL] [Abstract][Full Text] [Related]
6. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084 [TBL] [Abstract][Full Text] [Related]
7. miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil. Pessôa-Pereira D; Evangelista AF; Causin RL; da Costa Vieira RA; Abrahão-Machado LF; Santana IVV; da Silva VD; de Souza KCB; de Oliveira-Silva RJ; Fernandes GC; Reis RM; Palmero EI; Marques MMC BMC Cancer; 2020 Feb; 20(1):143. PubMed ID: 32087690 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil. Carraro DM; Koike Folgueira MA; Garcia Lisboa BC; Ribeiro Olivieri EH; Vitorino Krepischi AC; de Carvalho AF; de Carvalho Mota LD; Puga RD; do Socorro Maciel M; Michelli RA; de Lyra EC; Grosso SH; Soares FA; Achatz MI; Brentani H; Moreira-Filho CA; Brentani MM PLoS One; 2013; 8(3):e57581. PubMed ID: 23469205 [TBL] [Abstract][Full Text] [Related]
9. Gene-expression profiles in hereditary breast cancer. Hedenfalk I; Duggan D; Chen Y; Radmacher M; Bittner M; Simon R; Meltzer P; Gusterson B; Esteller M; Kallioniemi OP; Wilfond B; Borg A; Trent J; Raffeld M; Yakhini Z; Ben-Dor A; Dougherty E; Kononen J; Bubendorf L; Fehrle W; Pittaluga S; Gruvberger S; Loman N; Johannsson O; Olsson H; Sauter G N Engl J Med; 2001 Feb; 344(8):539-48. PubMed ID: 11207349 [TBL] [Abstract][Full Text] [Related]
10. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers. Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314 [TBL] [Abstract][Full Text] [Related]
11. Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage. Kote-Jarai Z; Matthews L; Osorio A; Shanley S; Giddings I; Moreews F; Locke I; Evans DG; Eccles D; ; Williams RD; Girolami M; Campbell C; Eeles R Clin Cancer Res; 2006 Jul; 12(13):3896-901. PubMed ID: 16818684 [TBL] [Abstract][Full Text] [Related]
12. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309 [TBL] [Abstract][Full Text] [Related]
13. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers. Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318 [TBL] [Abstract][Full Text] [Related]
14. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Holm K; Hegardt C; Gunnarsson H; Fagerholm R; Strand C; Agnarsson BA; Kilpivaara O; Luts L; Heikkilä P; Aittomäki K; Blomqvist C; Loman N; Malmström P; Olsson H; Johannsson OT; Arason A; Nevanlinna H; Barkardottir RB; Borg A Breast Cancer Res; 2010; 12(3):R42. PubMed ID: 20576095 [TBL] [Abstract][Full Text] [Related]
15. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling. Salmon AY; Salmon-Divon M; Zahavi T; Barash Y; Levy-Drummer RS; Jacob-Hirsch J; Peretz T Cancer Prev Res (Phila); 2013 Feb; 6(2):82-90. PubMed ID: 23341570 [TBL] [Abstract][Full Text] [Related]
16. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants. Machackova E; Claes K; Mikova M; Házová J; Sťahlová EH; Vasickova P; Trbusek M; Navrátilová M; Svoboda M; Foretová L Klin Onkol; 2019; 32(Supplementum2):51-71. PubMed ID: 31409081 [TBL] [Abstract][Full Text] [Related]
17. Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients. Fernandes GC; Felicio PS; Michelli RAD; Coelho AS; Scapulatempo-Neto C; Palmero EI Asian Pac J Cancer Prev; 2019 Jun; 20(6):1655-1660. PubMed ID: 31244284 [TBL] [Abstract][Full Text] [Related]
18. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers. Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626 [TBL] [Abstract][Full Text] [Related]
19. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors. Arnold JM; Choong DY; Thompson ER; ; Waddell N; Lindeman GJ; Visvader JE; Campbell IG; Chenevix-Trench G Breast Cancer Res Treat; 2010 Jan; 119(2):491-6. PubMed ID: 19189213 [TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families. Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]